Roche

Roche Takes Full Control of Genomic Profiler
Strategy

Roche Takes Full Control of Genomic Profiler

The $2.4 billion purchase of 44% of Foundation Medicine raises Roche's bet on the development of personalized cancer treatments and care.
By Matthew Heller | June 19, 2018
Read More
Roche Buys Flatiron in $1.9B ‘Big Data’ Move
Technology

Roche Buys Flatiron in $1.9B ‘Big Data’ Move

The real-world evidence Flatiron's record system collects "is a key ingredient to accelerate the development of, and access to, new cancer treatments."
By Matthew Heller | February 15, 2018
Read More
Facebook CFO: “Wicked Smart,” But No Ego
People

Facebook CFO: “Wicked Smart,” But No Ego

David Ebersman is perfectly suited for the maelstrom to come when the social-media giant's IPO hits the market.
By David McCann | February 2, 2012
Read More